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INTRODUCTION 
 
Until the last couple of decades, assessment of medical outcomes 
was strongly focused on gains in survival time, (i.e.) Quality of life. To 
most people, “Quality of life” refers to how good, desirable and 
enjoyable life as a whole is felt by the person in question1.  
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The impact of chronic eye disease causing severe visual 
impairment has been evaluated by objective means and has been 
considered infallible. Patients with these chronic eye diseases are 
treated with various methods and resolution of pathological process is 
expected out of it, from physician’s point of view. But, the real purpose 
of managing a chronic eye disease is to restore lost vision and to satisfy 
the patient as a whole with minimal adverse effects.  
In ophthalmology, the above quality of life and visual functions 
has been assessed with visual function assessment questionnaires 
(IND-VFQ / NEI VFQ) for many disease like cataract, ARMD2, 
glaucoma3, low vision patients4, surgical procedures likes ECCE Vs 
ICCE5,6,7,8  but the impact on health related quality of life following 
treatment in patients with chronic eye disease merits more detailed 
evaluation.  
Over the past decade, ophthalmic clinical trails are increasingly 
incorporating patient – perceived general health related and vision 
specific quality of life (QOL) instruments as secondary outcome 
measures.  The advantage of including a general health related QOL 
instrument along with disease specific instruments is that a general 
QOL instrument provides an important content for interpreting the 
disease specific data9. 
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 Hence, it was decided to analyze vision and health related quality 
of life in immunosuppressive treated uveitic patients and to verify the 
effect of treatment in the same population.  
 
 
 
 
 
                                                                       
 
 
 
 
 
QUALITY OF LIFE 
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 The quality of life is strictly a personalized issue.  Thus there is a 
strong argument that health related quality of life measurement should 
be based on patients defined issues10.  
 The health is just not absence of disease. It also involves social 
and psychological well being.  So, when we analyze that, the concept of 
well being of an individual or group of individuals have objective and 
subjective components.  
 
• Objective components  
1. Standard of living (refers to the usual scale of our 
expenditure, the goods we consume and the services we 
enjoy) 
2. Level of living (it consists of nine components like health, 
food consumption, education, occupation etc) 
• Subjective components 
Quality of life  
 
 
 
So, quality of life is a subjective well-being and it was defined by 
WHO11 as:  
“The condition of life resulting from the combination of effects of 
the complete range of factors such as those determining health 
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happiness (including comfort in the physical environment and 
satisfying occupation) education, social and intellectual attainments, 
freedom of action, justice and freedom of expression.  
It is “an individual’s perception of their position in life in the 
content of culture and value systems in which they live and in relation 
to their goals, expectations, standards and concerns12.  
Now a days people demand higher quality of life, which 
determines a persons satisfaction and it will be the ultimate goal of any 
treatment initiative.  
Hence there is a need for quality of life studies to find out, if our 
treatment increases the quality of life13 in all situations and if not think 
about remedial measures or alternative modalities.  
 
 
 
 
 
QUALITY OF LIFE INSTRUMENTS 
 
 QOL instruments are important tools that can complement and 
enhance the value of traditionally accepted test of outcome in the 
evaluation of clinical interventions14. 
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 QOL  measures have become the standard means of assessing the 
results of health care interventions and more controversially, the 
means of prioritizing fundings15. 
 QOL instruments fall into two categories16.  
 * Generic  :  which are broadly applicable across disease  
state and severities 
* Disease specific : which are designed to evaluate specific  
diagnostic states or patient populations.  
 Though it is easy to say that QOL assessment can be done by 
questions, it had many hurdles and many of them had been addressed 
to make the questionnaire a reliable modality.  
 The difficulties encountered are17,18,19 : 
a. what questions to be asked 
b. How many questions  
c. in what type of format 
d. Can it be used in a wide range of situations.  
Steps in Development of QOL instrument 
Step I : Generation of relevant issues 
Step II :  
Issues are converted into questions to get a dichotomous or 
polytomous response. 
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Each item is assigned a numerical score that corresponds to the 
rank of the patients response. 
Step III  
Grouping of items into different domains is thus based on 
developers own judgement20,21 on the basis of principal component 
analysis or reinforced  with confirmatory factor analysis. 
 Principal component analysis and factor analysis are used to look 
at the correlations of responses among items in the instrument.  
 If correlation is high, they probably assess the same variables.  If 
low then they are most likely to assess different variables.  
 Thus different items are grouped to form domains. 
Step IV 
 Developing a scoring scale for each domain.  Summary scores are 
developed for each domain by summing or averaging item scores. 
 
     The domain scores and instrument scores are called raw scores, 
which are treated as literal measurement scales.  
 Raw scores are converted into norms to allow comparison 
between individual performances with the performance distribution in 
the population. Then scales are tested for validity. 
Over all instrument scores is a sum or average of domain scores.  
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DEFINITION OF TERMS  
 
Instrument  
The set of questions used to assess daily functionary or other 
aspects of health related quality of life is called an instrument.  
Items 
 Individual questions in the instrument.  
Dichotomous Rating 
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 Patient is made to answer either true or false.  
Polytomous Rating22 
 Patient is made to answer from a list.  eg. choosing a response 
out of a list of ordered categories such as ratings of difficulty or 
frequency on a scale from 1 to 5.  
Domains or Subscales 
 The items in a questionnaire instrument might be grouped into 
domains or subscales each consisting of items, which are related and 
are assessing the same variable (eg. : distance vision, driving etc). 
 
 
 
 
NATIONAL EYE INSTITUTE – VISUAL 
FUNCTION QUESTIONNAIRE 
 
 
 
 National eye institute questionnaire, a targeted multi-
dimensional survey, was designed to represent the perspective of the 
patient with respect to visual disabilities and their impact on daily 
functioning.  
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The initial version of NEI – VFQ had 51 questions which 
represented 13 different subscales.  Despite the success of the longer 
field test version and its continued use, to enhance feasibility, a short 
version was planned.  
Development of NEI –VFQ – 2523 
 National eye institute sponsored the development of the VFQ-25 
with the goal of creating a survey that would measure the dimensions 
of self-reported vision targeted health status that are most important 
for persons who have chronic eye diseases. 
 Because of this goal, the survey measures the influence of visual 
disability and visual symptoms on generic health domains such as 
emotional well being and social functioning, in addition to task – 
oriented domains related to daily visual functioning.  
 NEI – VFQ – 25 is the product of an item reduction analysis of 
NEI – VFQ – 51.  It differs from the previous version by two things.  
1. It includes an extra driving item from the appendix of 
supplementary questions as part of the base set of items.  
2. Also, the revised scoring algorithm excludes the single item 
general health rating question from the calculation of the vision 
targeted composite score.  
Version 2000, the final version of the VFQ – 25 has the above 
difference from previous long versions (NEI – VFQ – 51) 
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Version 2000, has additional of 14 questions which can be added 
to make NEI – VFQ – 25 into a 39 item visual function questionnaire.  
Item Reduction Guidelines20 
 The following qualitative criteria were used to identify candidate 
items for NEI–VFQ  25 survey.  They are 
1. Retained items should have low missing data rates.  The 
inclusion of items that are most likely to be answered by most 
person will maximize the available information from each 
participants.  
2. To maintain breath of content, the intent is to have all 51-item 
VFQ’s constructs represented in the shorter survey, thereby 
remaining faithful to the range of topic areas mentioned by 
participants in the original focus groups. 
3. Priority is placed on retaining items with approximately normal 
distributions of responses over those with skewed distribution 
(large ceiling or floor effects). 
 
Once these 3 qualitative criteria are taken into consideration, the 
items that explain the greatest portion of variance for each of the 
original 51-item NEI – VFQ subscales in linear regression models are 
retained in the NEI – VFQ 25. 
Reliability24  
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 It is evaluated by estimating the internal consistency of the NEI 
– VFQ 25 which was calculated using Cronbach co-efficient α for each 
of the multi-item scales.  
 Internal consistency estimates for the NEI – VFQ 25 subscales 
ranged from 0.71 to 0.85 among persons with eye diseases while 51 
item scale had internal consistency estimates greater than or equal to 
0.70, indicating that the measure has acceptable reliability for group 
level comparisons.  
Validity 
 Validity assesses how well a measure adequately represents the 
domains or construct of interest20.  
 Correlations between the NEI – VFQ 25 versions of each 
subscale and their respective long term version were greater than 
0.9024.  
 On average, each NEI- VFQ – 25 subscale predicts 92% of the 
variance in the corresponding 51 item subscale score.23  
Subscales 
 The VFQ – 25 consists of a base set of 25 vision target questions 
representing 11 vision related subscales, plus an additional single item 
general health rating  question as shown in table 1(annexure)  
 All items in the VFQ – 25 are from the 51 item field test version; 
no new items were developed for use in the VFQ – 25. 
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 The guiding principles for the selection of the short form items 
included: 
1. Low item-level missing data rates 
2. Normal distribution of response choices 
3. Retention of items that explained the greatest proportion of 
variance in the 51 item subscales. 
Format 
 National Eye Institute visual function questionnaire, 2000 
version has two format. 
1. Interviewer administered  format 
2. Self administered  format 
NEI – VFQ – 25 takes approximately 10 minutes on average to 
administer in the interviewer format.  
The self administered version of the survey can also be used, 
however, its psychometric testing has not been done. 
 To ensure the comparability of scores across studies, it is our 
position that the order of items should not be changed.  
 The questionnaires were completed before the ophthalmic 
examination by the interviewer, to reduce the influence of the clinical 
encounter on patient responses.   
Scoring  
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 Scoring of NEI – VFQ – 25 with or without optional items is a 
two step process. 
Step I 
 Original numeric values from the survey are re-coded following 
the scoring rules outlined in table 2(annexure).   
 All items are scored so that a high score represents better 
functioning.   Each item is then converted to a 0 to 100 scale so that the 
lowest and highest possible scores are set at 0 and 100 points, 
respectively. In this format, scores represent the achieved percentage of 
the total possible score.  
 
 
 
Step II 
 Items within each sub-scale are averaged14 together to create the 
12 subscale scores.  Items that are left blank (missing data) are not 
taken into account when calculating the scale scores.  
 Subscales with at least one item answered can be used to 
generate a sub scale score.  Hence, scores represent the average for all 
items in the sub scale that the respondent answered.  
 Response 6 indicates that the respondent does not perform the 
activity because of reasons that are unrelated to vision.  If a respondent 
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selects this choice, the answer is treated as missing and an average of 
the remaining items is calculated.  
Composite Score Calculation  
 To calculate an over-all composite score for the VFQ – 25, simply 
average the vision– targeted sub-scale scores, excluding the general 
health rating question.  
 By averaging the sub scale scores rather than the individual 
items, we have given equal weight to each sub scale, where as averaging 
the items would give more weight to scales with more items.   
Formula23  
Score for each items with a non missing answer 
Mean       = Total number of items with non missing 
answers 
 
 100 : Best possible score,  0 : Worst possible score   
HEALTH RELATED QUALITY OF LIFE 
INSTRUMENT (SF 36/SF 12) 
 
 
 Over the past decade, ophthalmic clinical trials are increasingly 
incorporating patient – perceived general health related and vision 
specific quality of life (QOL) instruments as secondary outcome 
measures.  
 Health related QOL is a multidimensional concept that 
encompasses physical, emotional and social aspects associated within a 
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given disease or its treatment.  Measurement of health related QOL can 
provide helpful supplementary information on patient outcomes in the 
recovery process. 
 The advantage of including a general health – related QOL 
instrument along with disease specific instrument is that, a general 
QOL instrument provides an important context for interpreting the 
disease specific data.  
 The short form 36 (SF – 36) questionnaire is one of the most 
widely used health status evaluation tools.   It is a generic instrument 
developed by J.WARE for assessing patients with chronic disease25. 
 The SF – 36 consists of 36 questions, which require the 
respondent to rate items related to eight conceptual areas, including 
general health, ability to perform certain physical tasks, level of pain, 
emotional state and limitations in usual activities.  The SF-36 can then 
generate two composite scores  
• Physical composite scores (PCS) 
• Mental composite score (MCS) 
which provide an overall assessment of the respondent’s physical 
and mental health.  
Although very useful for a variety of health outcome evaluation 
purposes, the SF – 36 can take 10 to 12 minutes to complete.  Because 
of its length, the SF 36 is frequently considered to be too long for 
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inclusion in clinical studies with large scale measurement and 
monitoring efforts.  
An abbreviated version of the instrument containing a 12 
question subset of the SF-36 was developed; its development was 
started in the New England Medical Center in the spring of 1994.  
The SF–12 survey and scoring method was developed with the 
hope that, this shortened questionnaire could produce PCS and MCS 
composite scores that were comparable to the SF-36.  The average time 
to complete the SF-12 questionnaire is reported to be less than 2 
minutes.  
Improved study efficiency and cost saving may be realized by 
using a shorter questionnaire to measure general health status.  
The short form SF –12 health survey measures generic health 
concepts relevant across age, disease and treatment groups.  It provides 
a comprehensive, psychometrically sound and efficient way to measure 
health from the patient’s point of view by scoring standardized 
responses to standard questions.  
The SF-12 includes 8 concepts commonly represented in health 
surveys: physical functioning, role physical, bodily pain, general health, 
vitality, social functioning, role functioning, emotional and mental 
health.  Results are expressed into terms of two Meta scores: the PCS - 
12 and MCS-12. 
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Scoring of SF-12 
 The standardized response of each of the 12 questions in SF-12 
has its own numerical score, details of which are included along with 
questionnaire in annexure. 
 To calculate PCS and MCS scores, scored test items are 
normalized in a computer algorithm that generally requires a 
computer.  
 The PCS and MCS scores have a range of 50 to 100 and were 
designed to have a mean score of 50 and a standard deviation of 10 in a 
representative sample.  Thus, score greater than 50, represent above 
average health status.  
 On the other hand, people with a score of 40 function at a level 
lower than 84% of the population (one standard deviation) and people 
with a score less than 30 function at a level lower than approximately 
98% of the population (two standard deviation).  
           As computer algorithm for normalizing the scores of PCS and 
MCS  was not available, mean score of each subscale prior and after 
treatment were calculated and their significance tested by paired t-test 
value. 
 Compared with the SF-36, the disadvantages of using the SF-12 
include less–precise estimate of individual health and an inability to 
calculate summary scores when first item is left unanswered28.  
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Therefore, only patients who completed all of the SF-12 items were 
included in the statistical analysis.  
Validity of SF –12 
 The relationship between the PCS – 12 and MCS – 12 scores with 
the PCS-36 and MCS –36 was assessed using the Pearson correlation 
co-efficient as a measure of criterion and discriminant validity.  
Criterion Validity  
 Criterion validity refers to the correlation of a scale with an 
alternative measure of the trait or condition under study, ideally, a 
“gold standard’ that has been used and accepted in the field29.  
 No statistically significant difference were found between PCS 
and MCS scores from the SF – 36 compared  with that of SF –12. 
 
Discriminant Validity  
Discriminant validity refers to the ability of a scale to 
demonstrate a higher correlation with its intended study sample than a 
separate and less specific scale with the same sample.  
 The PCS–12 and MCS–12 scores were highly correlated with 
similar indicators (composite scores and subscales) of the SF-36, which 
has been shown to be a reliable and valid standardized measure of 
QOL30.  
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IMMUNOSUPPRESSIVES  
 
 Immunosuppressive agents by definition suppress development 
of at-least one type of immune reaction and they modify the specific 
immune sensitization of lymphoid cells.  A common feature of this 
family of drugs is their ability to interfere with synthesis of nucleic 
acids and or proteins31.    
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 The major immunosuppressives used in uveitis was divided into 
alkylating agents and antimetabolites along with noncytotoxic       
immunosuppressive medications such as cyclosporine.  
 Immunosuppressive agent represents the final rung in our 
stepladder approach to the medical treatment of ocular inflammatory 
disease32.   The safe use of these drugs begins with exclusion of 
infections, mechanical or other treatable causes of ocular 
inflammation.  
 Informed consent is obtained and documented;  the patient is 
given an explanation of the potential risks and benefits involved in this 
therapeutic modality.  Initially steroids are used in maximally tolerated 
doses. 
 The choice of the agent is individualized for each patient and 
depends on a variety of consideration, including the underlying 
disease, the patient’s age and the medical status.  Patients are carefully 
screened for risk factor which might preclude the use of certain 
immunosuppressives (e.g. Hepatic disease for methotrexate, and renal 
disease for cyclosporine). 
 Patients are also informed of the proper dosing and intake, 
potential adverse reactions and alternative to therapy.  
Indication  
 Absolute    : 1.  Behcet’s syndrome 
      2. Rheumatoid Sclero-uveitis 
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      3. Sympathetic ophthalmia 
      4. VKH syndrome 
      5. Serpiginous choroidopathy   
 Relative    : 1.  Intermediate uveitis   
      2. Retinal vasculitis 
      3. Chronic cyclitis  
 Questionable   : Children with intermediate 
uveitis  
 
Guidelines  
Prior to initiation of therapy with any cytotoxic agents, it is 
important to consider these guidelines.  
1. Absence of infection / masquerade syndrome. 
2. Absence of hematological contra-indications. 
3. Meticulous follow up by ophthalmologist or internist or a 
medical oncologist, if necessary. 
4. Objective evaluation of the disease process. 
5. Informed consent. 
Mode of Action  
 Immunosuppressive agents as by definition suppress 
development of at least one type of immune reaction.  A common 
feature of this family of drugs is their ability to interfere with the 
synthesis of nucleic acids and / or proteins.  
     Purine synthesis    Pyrimidine synthesis 
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* Azathioprine 
* Methotrexate  
 
 
 
 
 
 
 
 
 
 
 
 
 
STERIODS AS IMMUNOSUPPRESIVE 
 Corticosteroids are the mainstay of anti-inflammatory therapy 
for most types of uveitis, and effectively suppress the inflammatory 
response regardless of its cause.  
Mechanism of Action  
The anti-inflammatory effects are initiated when the 
corticosteroid molecule enter the target cell and combines with the 
Ribonucleotides 
Deoxyribonucleotides  
* Methotrexate 
DNA 
* Cyclophosphamide 
* Chlorambucil  
RNA 
T – RNA, M-RNA, R-RNA 
Proteins 
* Colchicine             Microtubule Enzymes 
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glucocorticoid receptor within the cytoplasm.  This steroid receptor 
complex is then transported to the nucleus, affects the DNA 
transcription resulting in change in messenger RNA production, 
protein synthesis and cell function. Glucocorticoid receptors are 
present not only on all cells of the immune system but also in iris, 
ciliary body and corneoscleral tissue of eye.  
Corticosteroids appear to act at the recognition and proliferative 
phase of immune response, therapy suppressing both   B cell and T cell 
mediated response which eventually lead to impairment of both cell 
mediated immunity and humoral immunity.  
Routes of Administration 
Corticosteroids can be delivered to eye by three routes.  Topical 
steroids which have a good therapeutic effect in anterior segment, have 
poor penetrance into posterior segment.  In that instance, periocular 
steroid via posterior-subtenon deposteroid injection is being used to 
treat intermediate and posterior uveitis. Major disadvantage of this 
route is elevated intraocular pressure.   
It is in case of bilateral uveitis or in patients who have severe 
unilateral inflammation and who are intolerant to or unresponsive to, 
periocular injections, systemic corticosteroids are employed.  
Principles of systemic corticosteroid therapy in uveitis32 
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1. Use enough, soon enough, often enough and long enough to 
secure desired results.  
2. Suppress inflammation until the pathogenic mechanism burn 
out.  Increase dosage immediately if there is recrudescence. 
3. If systemic therapy lasts for more than 2 weeks never stop 
abruptly at a higher dosage as it precipitates addisonian crisis – 
taper dose slowly. 
4. Corticosteroid should not be used as the last resort; they should 
be started as soon as indicated.  
5. One should start with a high dosage and taper.  
6. The steroid dosage should not be tapered with a pre determined 
plan, but accordingly to the disease response.  
 
 
 
 
Indications 
Following are the ophthalmic indications for use of 
corticosteroids.  
Eyelids  
• Contact dermatitis  
• Discoid lupus 
• Chemical burns 
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Conjunctiva 
• Allergic disease (vernal, GPC) 
• Ocular cicatrical pemphigoid 
Cornea 
• Disciform keratitis 
• In peripheral ulcerative keratitis 
• Graft rejection  
• chemical burns without epithelial defect 
Sclera 
• Scleritis 
Orbit  
• Pseudotumours 
• Grave’s orbitopathy 
 
 
Uvea  
• Anterior uveitis 
• Pars planitis 
• Posterior uveitis 
• Sympathetic ophthalmia 
• VKH syndrome 
• Endophthalmitis 
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• Vasculitis / choroiditis 
Retina 
• Cystoid macular oedema 
• Acute retinal necrosis 
Neuro-opthal 
• Optic neuritis 
• Temporal arteritis 
• Ocular myasthenia 
Others 
• Post operative 
• Trauma 
 
 
Contra Indications  
¾ Absolute  
1. Known or suspected systemic fungal infections  
2. Known hypersensitivity to steroid formulation  
3. Systemic infections like toxoplasmosis, herpes and                         
tuberculosis. 
¾ Relative 
1.  Severe cardiovascular disease  
2.  Psychiatric patients 
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3.  Previous GI problem 
4.  Diabetic patients 
5.  Musculoskeletal disease 
6.  Pregnancy 
Dosage 
Dose of oral corticosteroids, which in excess of the daily 
endogenous output of hydrocortisone (about 20 mg), are necessary to 
produce the anti-inflammatory or immunosuppressive action.  In this 
study, patients receiving steroid dose in excess of 1mg / kg/d is 
considered as immunosuppressive dosage and included in this study.  
Initial dose  : 1mg/ kg/d 
Max dose   : 60-80 mg/kg/d 
Maintenance dose  : ≤10mg/d 
Tapering 
When high dose oral corticosteroids are given for more than 2 
weeks, it should never be discontinued abruptly, as it precipitates an 
addisonian crisis.   
A slow and steady tapering is done, at a rate dictated by the 
clinical condition, so that a recurrence of inflammation is not 
precipitated.  
Tapering Schedule  
Initial Dose  Method of Tapering 
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> 40 mg/d : decrease by 10mg / d ,every 1-2 weeks 
40-20 mg/d : decrease by 5mg/d, every 1-2 weeks 
20-10mg/d : decrease by 2.5mg/d, every 1-2 weeks 
10-0mg/d : decrease by 1-2.5 mg/d, every 1-4 
weeks 
 
Side Effects and its Management  
Corticosteroid therapy produces both ocular and systemic side 
effects irrespective of the route of administration.  Although,  topical or 
periocular administration may result in significant systemic 
absorption, untoward systemic complications are for more likely after 
oral or parentral therapy, and their frequency is both dose and duration 
dependent.  
Alternate day therapy produces less severe and fewer steroid – 
induced side effects and does not disturb the hypothalamo-pitutary 
axis.40 
 
I. Systemic  
1. Sodium and fluid retention  
2. Hypertension  
3. Osteoporosis 
4. Peptic ulcer 
5. Increased appetite 
6. Poor wound healing 
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7. Acne 
8. Increased sweating  
9. Moodiness 
10. Weight gain  
11. Diabetes 
12. Increased susceptibility to infections 
13. Menstrual irregularity 
14. Rarely thromboembolism 
II. Ocular 
1. Posterior subcapsular cataract 
2. Glaucoma 
3. Central serous retinopathy 
Corticosteroid induced bone loss is a dose and duration 
dependent side effect. 
Bone loss is inevitable during steroid therapy and commences 
within days of starting treatment.  The rate of loss is greatest within the 
first 6 months during which time, typically 4-5% of bone is lost35. 
Eventually osteoporosis occurs in up to 50% of patients36.   
Trabecular bone is particularly affected, so effects are more 
marked in the spine and proximal femur.  There is a 2.5-3 times 
increased risk of fracture compared with a control population.  
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Currently it is recommended that all patients should be given 
supplemental calcium (1000 / 1500 mg/d) and vitamin D (400 to 800 
U/day) to retard bone loss33. 
Patients on long term corticosteroids ideally should be 
monitored with yearly bone density measurement and treated with 
biphosphonates (like etidronate or pamidronate) if bone loss is 
documented.  
Patients on systemic corticosteroids, particularly those with a 
history of peptic ulcer disease or gastro esophageal reflux, benefit from 
prophylactic therapy with either an H2 blocker (eg: Ranitidine, 150mg 
two to four times a day) or a proton pump inhibitor (e.g.: omeprazole, 
20mg/d, half an hour before food). 
Ideally, corticosteroids should be taken as a single dose in the 
morning.  This is not only more physiologic, because the natural peak 
of adrenal corticosteroid production occurs in the morning, but also it 
allows the patient to sleep better. 
Secondary open-angle glaucoma is most likely to occur after 
prolonged topical therapy with potent steroids.  A more pronounced 
steroid-induced IOP increase is noted in patients with open angle 
glaucoma, diabetics and high myopes. 
Posterior subcapsular cataract (PSCC) arise in a dose and 
duration dependent manner after long term oral corticosteroid therapy.  
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Children and patients with diabetes are more prone to develop.   The 
mechanism of corticosteroid –induced cataract formation is believed to 
involve the binding of glucocorticoids to lens fibers, leading to 
biochemical alterations with protein aggregation in the cells and a 
change in refractive index.  
Once established, the opacity is generally not reversible.  
However, regression of PSCC has been reported in children when 
therapy is discontinued.37 
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1. Unilateral Visual Impairment and Health related 
quality of life : the blue mountains eye study 
 E – M Chia, P Mitchell Rochtchina,S Foran,JJ Wan,JJ Wand 
BJO 2003; 87: 392-395. 
 The study is aimed at determining the impairment of unilateral 
vision on health related quality of life (HRQOL) in an older community.  
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Study group, which includes 4433 eligible non –institutionalized 
permanent residents who was administered health survey 
questionnaire (SF36) in a door to door census.  Study showed 
measurable impact on HRQOL in those patients who had moderate to 
severe non –correctable unilateral visual impairment caused by eye 
diseases like cataract.  
2. Vision related quality of life in people with central 
retinal vein occlusion using the 25-item National Eye 
Institute Visual function questionnaire 
Vincent A. Deramo, Terry A. Cox, Arjumand B. Syed, Paul P. Lee; 
Sheron Fekrat. Arch Ophthalmol. 2003; 121: 1297-1302. 
Fifty one consecutive patients participated in this study.  Forty 
eight patients had unilateral CRVO, and 5 had bilateral CRVO. All 
patients including reference group were administered NEIVFQ – 25 
and analyzed result showed significantly decreased QOL when 
compared to reference group in patients with CRVO.  This decrease in 
VFQ – 25 scores is related to the degree of visual loss in the better 
seeing eye and the overall systemic health of the patient.  
3. Vision related quality of life in people with bilateral 
severe Age Related Macular Degeneration 
Mark T. Cahill, Avie D. Banks; Saundra S. Stinnett, Cynthia A. 
Toth; Ophthalmology 2005; 112: 152-158.  
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Seventy patients with bilateral severe age related macular 
degeneration were administered NEI–VFQ–25 and SF – 12 
questionnaires before macular translocation with 360o peripheral 
retinectomy.  According to this study, bilateral central vision loss due to 
ARMD had a profound impact on vision related QOL and had no 
relation with general health problems.  
4. Vision functioning and  General Health Status in 
Patients with Uveitis  
M.Schitman, Gordon Jacobsen, Scolt M Whitcup. Arch 
Ophthalmol 2001; 119: 841-849. 
This study conducted at the uveitis clinics at National Institute of 
health, Bethesda, enrolled seventy- six patients with uveitis over a          
period of 14 months and were administered NEI – VFQ – 25 and SF –
36  
 
questionnaires to measure the visual functioning and quality of life in 
those patients.  Results showed markedly poorer visual functioning and 
general health status than normal subjects.  More severe the uveitis, 
poorer  the quality of life.  
5. Validity of the SF-12 quality of life instrument in 
patients with retinal diseases.  
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Devise R. Globe, Stainslav Levin; Tom S. Chang; Paul J. 
Mackenzie; Stanley Azen; Ophthalmology 2002; 109: 1793-1798. 
As SF-36 questionnaire is too long and takes 12 minutes to 
complete, inclusion in clinical studies other then health outcome 
evaluation has been discouraged.  Smaller version of this, SF-12 is 
being used widely to study health related quality of life in ophthalmic 
research, which is short and takes only 2 minutes.  Above study was 
done to investigate the construct validity and reliability of the SF-12 
with the SF-36 composite scores in patients with retinal diseases.   The 
study gave the conclusion that SF-12 is a valid measure and the benefit 
of reduced administration time makes the SF-12 a recommended 
general quality of life outcomes tool. 
 
 
6. Correlation between visual function and visual ability in 
patients with uveitis.  
Gardiner AM, Armstrong RA, Danne MCM, Murray P;  BJO; 
2002; 86: 993-996. 
The study compared the high (monocular and binocular) and low 
(binocular) contrast log MAR letter activities using a Bailey- Louis 
chart and contrast sensitivity with the vision related quality of life 
 41
answer using vision specific quality of life (VQOL) questionnaire in 
uveitis patients.  
The study concluded that Binocular high contrast visual acuity is 
a good measure of how uveitis patients perform in real life situations.  
Vision related quality of life is worst in younger patients with poor 
binocular visual acuity.  
7. Health related quality of life in patients with cataract 
and glaucoma  
Lec BL., Wilson MR; J.Glaucoma 2000 Feb; 9(1): 87-94. 
Increasing severity of glaucoma has been shown to be negatively 
related to vision targeted quality of life.  The relationship between 
increasing severity of glaucoma and overall self perceived health status 
is inconclusive. 
 
 
8. Quality of Life associated with visual loss. A time trade 
off utility analysis comparison with medical health 
status   
Melissa M. Brom, Gary C. Brown, Sharma S, Busbee B. 
Ophthalmol 2003; 110: 1076-1081.  
This paper presents a cross sectional utility value assessment to 
assess the visual utility values of patients with ocular disease and to 
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compare these values with those of patients with systemic health 
status.  The conclusion is that visual loss is associated with a 
substantial and measurable diminution in quality of life.  
9. The Madurai intraocular lens study III. Visual 
functioning and Quality of Life outcomes 
Astrid Fletcher, V. Vijay Kumar, S. Selvaraj, R.D. Thulasiraj Leon 
B, Ellwein; Am. J. Ophthalmol. 1998; 125: 26-35. 
It is a randomized control trial involving 3450 bilaterally vision 
impaired patients aged between 40 to 75 years of age with operable 
cataract.  Patients were administered 31 item visual functioning 
questionnaire and 12 item quality of life questionnaire before and at 6 
months and 12 months after surgery.  Method of surgery was randomly 
assigned (either ECCE with IOL or ICCE). Conclusion of this study was 
that ECCE with IOL is better than ICCE and the visual functioning is 
better with highly significant P value (P<0.0001). 
10. Treatment of uveitis with immunosuppressive agents.  
Narsing A Rao; Buddi Rajeev; Indian journal of Ophthalmology; 
Oct 1998; 41(3):107-113. 
This article has comprehensive details about principle of treating 
uveitis with steroids, various methods of administration and 
monitoring of its side-effects.  It also includes indications and action of 
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commonly used immunosuppressives in uveitis with brief mention 
about its toxicity, precautions and monitoring for those toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM 
 
 
 To assess the vision and health related quality of life in patients 
with sight – threatening uveitis treated with immunosuppressive 
medication using 25 items National Eye Institute visual function 
questionnaire and short form 12 health survey. 
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Inclusion Criteria  
1. Uveitis patient, started on immunosuppressive medication  
2. Patient who knows Tamil  
3. Willing to participate in study  
4. Age > 18 years.  
 
Exclusion Criteria  
1. Patient either not willing to participate or who doesn’t know 
Tamil.  
2. Patient who cannot come for follow up  
3. Who has hearing / speech difficulties  
4. Age < 18 years 
 
 
 
PATIENTS AND METHODOLOGY 
Patient Selection  
 This study was conducted at uveitis clinic in a tertiary eye care 
centre in South India, which is a major referral centre for 
Ophthalmology.  
 All patients with sight – threatening uveitis who fit into inclusion 
criteria were enrolled over a period of six months from April 2004 to 
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October 2004.  All patients were explained about the purpose of study 
and consent was obtained.  
Data Collection  
 During the period of six months, 42 patients were enrolled and 
demographic data’s were collected.  The SF-12 and NEI – VFQ 25 
questionnaires were applied by an interviewer and was made sure that 
only one person apply the questionnaire, the first time and also when 
the patients come back after six months. The questionnaires were 
completed before the ophthalmic examination to reduce the influence 
of the clinical encounter on patient’s response.  
 All patients were requested to give their response for questions 
from the options given below each question.  After responses were 
obtained, clinical data like visual acuity, onset, location of 
inflammation, laterality, level of inflammation, etiological diagnosis 
and type of immunosuppressive medication prescribed were recorded.  
Patients were explained about the importance of follow up and 
potential side effects of medication.  
 The enrolled patients were asked to review on a regular basis 
based on their uveitis status and the questionnaires were reapplied six 
months from the date of starting immunosuppressive medication.  The 
patients who did not turn up for review, were telephoned and  
explained about importance of review and risk involved in having 
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medication without monitoring and were asked to come for follow up. 
Data of patients who did not turn up after six months were eliminated 
and patients who gave response prior and after six months of treatment 
were compared. 
Statistical Methods 
  Original numeric values given as a response were recoded 
by following the scoring rules outlined for each of the questionnaires 
and these questions were grouped under their respective subscales in 
NEI-VFQ-25 and under PCS and MCS in health survey.  
 After grouping into sub-scales, the mean composite score, before 
and after treatment were calculated after averaging the scores of the 
respective subscale and by using the formula given below. Their 
significance is tested by using paired t-test value.  
      Score for each items with a non missing answer 
       Mean  = 
    Total number of items with non missing 
answers 
 
RESULTS 
 
 42 patients were enrolled for this study over a period of six 
months and 35 patients came for follow up with follow up rate of 
83.3%.  The mean age of the patients were 36.8 years with females 
constituting 52.4% of total patients (table 1 & 2).  Among these 
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patients, 64.3% of them are literate and 57.1% of them are unemployed 
(table 3 & 4). Diminished vision alone was a common compliant 
constituting 40.5%, and other complaints constituting the rest as 
shown in table 5. 
 Nearly 80% of them had uveitis in both eyes with acute onset 
constituting 54.8% of them (table 6 & 7).  61.9% of these patients   had  
pan-uveitis ,16.7% of them had posterior uveitis, followed by anterior 
uveitis of 11.9% and intermediate uveitis of 9.5% (table 8).  78.6% of 
them had granulomatous uveitis with VKH syndrome being the most 
common etiological diagnosis (table 9 & 10). 
 71.4% of patients were treated with a combination of 
methotrexate and high dose oral corticosteroids and 26.2% of patients 
were given oral corticosteroids with a dose of 1mg / kg /day, which was 
considered as an immunosuppressive dose in this study.  Only four 
patients (2.4%) were treated with Azathioprine and high dose oral 
corticosteroids (table 11). 
Visual Function  
 The mean score of general health subscale showed slight dip in 
its value following treatment with a p value of 0.08, whereas other 
subscales like general vision, ocular pain, near activities, distance 
activities, mental health, social functioning, role difficulties, 
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dependency, colour vision and peripheral vision had significant 
increase in mean score following treatment with a significant p value.  
 Driving subscale had an improvement in its mean value 
following treatment, with p value of 0.066. 
Health Status  
Physical Composite Score (PCS) 
 General health question did not generate any mean value on both 
the occasions as only “POOR” option had a score of –2 with rest of all 
having a score of 0. 
 Bodily pain showed significant improvement following treatment 
with a p value of < 0.001. Rest of the components of PCS like physical 
functioning, role physical showed no significant change. 
 Overall physical composite score had a p value of 0.008. 
Mental Composite Score (MCS) 
 Mental health, role emotional and social functioning subscale 
had significant rise in mean value following treatment, whereas vitality 
had no significant change, which is an emotional perception of having 
lot of energy or not.  
 
Table – 1 
 
N 
Minimum 
(in years) 
Maximum 
(in years) 
Mean 
(in years) 
Standard 
Deviation Age 
43 14 69 36.81 14.681 
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Table – 2 
Sex 
 
 Frequency Percent 
Male 20 47.6 
Female 22 52.4 
Total 42 100.0 
 
 
Table – 3 
 
Educational Qualification 
 
 
 Frequency Percent 
Literate 27 64.3 
Illiterate 15 35.7 
Total 42 100.0 
 
 
Table – 4 
Occupation 
 Frequency Percent 
Employed 18 42.9 
Unemployed 24 57.1 
Total 42 100.0 
 
 
Table – 5 
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Complaints 
 
 Frequency Percent 
Diminished vision(DV) 17 40.5 
DV+ Pain 12 28.5 
DV +Redness 4 9.5 
DV +Floaters 4 9.5 
DV +Redness +Floaters 1 2.4 
Pain + Redness 2 4.8 
Pain +Redness+ Photophobia 1 2.4 
Reduces + Floaters 1 2.4 
Total 42 100.0 
 
 
 
 
 
Table – 6 
Laterality 
 
 Frequency Percent 
Right Eye 4 9.5 
Left Eye 5 11.9 
Bilateral 33 78.6 
Total 42 100.0 
 
Table – 7 
Onset  
 
 Frequency Percent 
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Acute 23 54.8 
Chronic 19 45.2 
Total 42 100.0 
  
Table – 8 
Location  
 
 Frequency Percent 
Anterior 5 11.9 
Intermediate 4 9.5 
Posterior 7 16.7 
Pan uveitis 26 61.9 
Total 42 100.0 
Table – 9 
Severity  
 
 Frequency Percent 
Granulomatous 33 78.6 
Non granulomatous 7 16.7 
Others 2 4.8 
Total 42 100.0 
 
Table – 10 
Etiological Diagnosis 
 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Bechet’s syndrome 4 9.5 9.5 9.5 
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Diffuse scleritis 1 2.4 2.4 11.9 
Endophthalmitis 1 2.4 2.4 14.3 
GHPC 1 2.4 2.4 16.7 
Leptospiral vasculitis 1 2.4 2.4 19.0 
Nodular scleritis 1 2.4 2.4 21.4 
Pars planitis 4 9.5 9.5 31.0 
Posterior scleritis 1 2.4 2.4 33.3 
Anterior scleritis 1 2.4 2.4 35.7 
Retinal vasculitis 2 4.8 4.8 40.5 
Rheumatoid sclero-
uveitis 
1 2.4 2.4 42.9 
Sympathetic Ophthalmia 4 9.5 9.5 52.4 
VKH syndrome 20 47.6 47.6 100.0 
Total 42 100.0 100.0  
 
Table – 11 
Treatment 
 
 
 Frequency Percent 
High dose oral Corticosteroids 11 26.2 
Azathioprine + High dose oral Corticosteroids 1 2.4 
Methotrexate+ High dose oral Corticosteroids 30 71.4 
Total 42 100.0 
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GENDER 
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Male Female
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SEVERITY 
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VISUAL FUNCTION AND QUALITY OF LIFE 
Descriptive Statistics 
 
General 
Health 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 100.00 94.2857 18.27659 
Post-treatment 35 50.00 100.00 89.2857 15.20172 
0.087 
 
 
General 
Vision  
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 100.00 28.5714 30.40345 
Post-treatment 35 .00 100.00 68.5714 30.52413 
0.000 
 
 
Ocular Pain N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 12.50 100.00 60.3571 30.08653 
Post-treatment 35 12.50 100.00 90.7143 19.25612 
.000 
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Near 
Activities 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 33 .00 100.00 47.9798 29.31734 
Post-treatment 31 8.33 100.00 89.2473 23.68715 
0.000 
 
 
 
 
 
Distance 
Activities 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 32 .00 100.00 50.2604 32.41230 
Post-treatment 32 25.00 100.00 93.2292 15.32759 
0.000 
 
 
 
Mental 
Health 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 68.75 33.5714 23.68246 
Post-treatment 35 18.75 100.00 82.8571 24.17494 
0.000 
 
 
 
Social 
Functioning 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 33 .00 100.00 46.5909 31.75725 
Post-treatment 34 25.00 100.00 93.7500 16.06391 
0.000 
 
 
 
Role 
Difficulties 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
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Pre-treatment 35 .00 100.00 44.2857 36.67510 
Post-treatment 35 .00 100.00 80.0000 29.73535 
0.000 
 
 
 
 
 
 
Dependency N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 100.00 41.6667 40.62421 
Post-treatment 35 16.67 100.00 87.8571 23.94360 
0.000 
 
 
 
Driving N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 5 16.67 75.00 46.6667 20.91650 
Post-treatment 5 16.67 100.00 86.1111 34.02069 
0.066 
 
 
 
Colour Vision  N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 100.00 65.7143 33.25797 
Post-treatment 35 50.00 100.00 68.5714 14.95792 
0.000 
 
 
 
Peripheral 
Vision  
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 100.00 73.5714 33.72840 .001 
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Post-treatment 35 75.00 100.00 97.1429 8.07007 
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SF-12 HEALTH SURVEY 
Descriptive Statistics 
Physical composite score: 
 
 
General 
Health 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 .00 .0000 0.00000 
Post-treatment 35 .00 .00 .0000 0.00000 
1.000 
 
 
Bodily Pain N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 2.00 .8000 .71948 
Post-treatment 35 .00 1.00 .2000 .40584 
.000 
 
 
Physical 
Functioning 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 3.50 .2571 .72123 
Post-treatment 35 .00 1.00 .0286 .16903 
0.056 
 
 
Role Physical N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 1.50 1.3714 .42604 
Post-treatment 35 1.50 1.50 1.5000 .00000 
.083 
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Overall PCS 
score 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 .00 1.83 .6782 .29133 
Post-treatment 35 .50 .83 .5429 .8424 
.008 
 
 
Mental composite score 
 
Mental 
Health 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 -10.50 .00 -7.6000 2.70566 
Post-treatment 35 -10.50 .00 -2.2571 2.77958 
.000 
 
 
 
Vitality N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 -5.00 .00 -.8286 .85700 
Post-treatment 35 -1.00 .00 -.6286 .49024 
.371 
 
 
 
Role 
Emotional 
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 -6.50 .00 -1.2143 2.50965 
Post-treatment 35 -6.50 .00 -5.2000 2.63796 
.000 
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Social 
Functioning  
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 -6.00 .00 -6.7714 2.05921 
Post-treatment 35 -8.00 .00 -2.0000 2.65684 
.000 
 
 
 
Overall MCS 
Scores  
N Minimum Maximum Mean 
Std. 
Deviation 
P 
Value 
Pre-treatment 35 -6.83 -1.33 -4.2048 1.12102 
Post-treatment 35 -5.00 -1.33 -2.9238 .82282 
.000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Uveitis is a major cause of ocular morbidity and is reportedly 
responsible for an estimated 30,000 new cases of legal blindness 
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annually in the United States.41 It’s high prevalence in India was 
highlighted by Dandona et al42 and it warranted an immediate and 
effective management. High dose oral corticosteroids and cytotoxic 
medications are being used as a final rung in management inspite of its 
documented potential side effects. Henceforth, it was decided to assess 
vision related quality of life in immunosuppressive treated uveitic 
patients and to know the impact of its side effects on their health 
status. 
General health of these patients on immunosuppressive 
medication showed slight decrease in mean score after six months due 
to the side effects like gastritis, weight gain, emotional influence on 
taking too many pills etc, whereas bodily pain showed  significant 
improvement with a p value of <0.001, as their ocular pain interfering 
with daily activities showed improvement with medication. Treatment 
had no influence on physical functioning and vitality and it didn’t cause 
any physical morbidity.  
Visual functions like near and distance activities, role difficulties 
pertaining to vision showed marked improvement with a p value of 
<0.001. It almost eliminated the dependency of these patients, as most 
of them had an attender during their first visit. Emotional disturbance 
experienced by these patients due to  defective vision  showed  
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significant relief with treatment, as indicated by rise in post treatment 
mean scores of mental health and MCS.  
Social functioning  like visiting people in their homes or 
attending marriages which was influenced by defective vision and 
ocular pain, showed significant change after six months of treatment. 
As 53% of patients in this study are females and more than half of the 
males had no experience of driving, driving subscale questions were 
answered only by 14% of them (only 5 patients) and had  moderate 
effect with a p value of < 0.066, even though, the mean value had a 
significant improvement . 
Overall, the visual function, vision related quality of life and 
mental health of these patients improved significantly, following 
treatment of sight–threatening uveitis with immunosuppressive 
medication, with slight dip in general health status due to its side 
effects.  
 
 
 
 
 
CONCLUSION 
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 Vision and health related quality of life in forty two uveitic 
patients, who were on immunosuppressive medication were evaluated 
prior to and six months following treatment showed  significant 
improvement in: 
¾ Visual function and vision related quality of life . 
¾  Mental health . 
¾ Social functioning  
¾ Ocular pain.  
Treatment almost eliminated the dependency and role 
difficulties in these patients. Study showed the general health status 
was affected due to its side effects and medication had no influence on 
physical functioning. The influence of potential side effects of 
medication on health status in these patients on prolonged course 
needs to be assessed.  
So, judicious use of high dose oral corticosteroids and any 
cytotoxic medication as a final step in management of sight threatening 
uveitis is important and it does improve the quality of life significantly 
in uveitic patients, even though it has a mild impact on general health 
status of these patients due to its side effects. 
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ANNEXURE 
 
Table 1 
Averaging of Items to Generate VFQ – 25 sub-scales 
 
Scale 
Number of 
Items 
Items to be averaged  
1.  General health  1 1 
 73
2.  General vision  1 2 
3.  Ocular pain  2 4, 19 
4.  Near activities  3 5, 6, 7 
5.  Distance activities  3 8, 9, 14 
6.  Social functioning  2 11, 13 
7.  Mental health 4 3, 21, 22, 25 
8.  Role Difficulties  2 17, 18 
9.  Dependency  3 20, 23, 24 
10.Driving  3 15c, 16, 16a 
11.Colour vision  1 12 
12.Peripheral vision  1 10 
 
 
 
 
 
Table 2 
Scoring key: Recoding of items 
 
Item Numbers Precoded choices 
To recoded value 
of: 
1 100 
2 75 
3 50 
4 25 
1, 3, 4, 15c, 2 
5 0 
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1 100 
2 75 
3 50 
4 25 
5 0 
5, 6, 7, 8, 9, 10, 11,  
12, 13, 14, 16,16a 
6 * 
   
1 0 
2 25 
3 50 
4 75 
17, 18, 19, 20, 21, 22,  
23, 24, 25 
5 100 
 
 
 
Table 3 
  
Averaging of items to generate SF-12 subscales 
 
 
Physical Composite Score 
(PCS) 
Questions 
1.  General health  1 
2.  Bodily pain  8 
3.  Physical function  2, 3 
4.  Role – physical  4, 5 
 
 
Mental Composite Score Questions 
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(MCS) 
1.  Mental health  9,11 
2.  Vitality  10 
3.  Role emotional  6,7 
4.  Social functioning  12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
Name :    DATE :  
Age :    Presentation :__________ 
Sex  :    Male    Female Start of immuno suppressives 
_________ 
 
     1st Follow up __________________ 
     2nd Follow up__________________ 
 
Educational  
Qualification : Literate       Illiterate        
 
Occupation  : Employed    Unemployed   
  
Income   :  
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Personal History  : DM       SHT     Cardiac      
 Asthma     Any allergy     
Other  ____________ 
 
Complaints   :   Pain             Photophobia            DV      
Redness        Floaters         
Duration   : 
 
Laterality   : RE   LE    Bilateral    
 
Diagnosis   : Acute   Chronic     
Anterior  Intermediate   Posterior  Pan 
uveitis Granulomatous   
nongranulomatous   
Etiological  / Specific Diagnosis : ____________________ 
Treatment  : Cyclophosphamide   Chlorambucil         
Azathioprine    Cyclosporine A       
Methotrexate   Corticosteriods   *Local      
others                 *Systemic  
  
 
Dosage  :       ___________________________________ 
Examination           First Visit           6th  month  
         RE  LE      RE     LE  
  
1. Visual acuity                      
2. Band keratopathy                    
3. KP’s (G/N)            
4. Anterior chamber  
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Cells                 
 Flare                
5. Iris atrophy             
6. Posterior synechiae              
7. NVI               
8. Iris nodules (K/B)              
9. Cataract             ________   _______         
10. AVF Cells                  
11. Vitreous opacities (E/H)             
12. Vasculitis                   
13. Granuloma                     
14. Exudative RD                     
15. Retinitis                       
16. Choroiditis                     
17. IOP                      
Investigations  
18.  Hemoglobin %   ________   _______             
 TC    ________   _______            
 DC    ________   _______             
 ESR    ________   _______             
 Platelet count   ________   _______             
 Peripheral smear   ________   _______             
 Bleeding time  ________   _______      
 Clotting time   ________   _______             
 Mantoux    ________   _______             
 VDRL   ________   _______             
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 Blood Urea   ________   _______             
 S. Creatinine   ________   _______             
 Liver function test   
 * SGOT  ________   _______   
  * SGPT  ________   _______   
 * Serum Bilirubin  ________   _______   
 Urine  
 *Albumin   ________   _______   
 * RBC’s   ________   _______ 
 
Systemic Side effects  
 Headache           
 Increased appetite         
 Weight gain         
 Fever           
 Poor wound healing          
 Increased sweating        
  
 Arthritis           
 Gingival hyperplasia          
 Alopecia         
 Hirsuitism           
 Pedal edema          
 Menstrual irregularity        
 Acne            
 Diarrhea           
 79
 Ulcerative stomatitis         
 Nausea           
 Vomiting           
 Epigastric pain           
 Hematuria           
 Postural Hypotension          
 Moodiness          
 Insomnia          
 
 
 
 
VISUAL FUNCTIONING QUESTIONNAIRE –25 
 
PART – I 
 
General Health and Vision 
1. In general, would you say your overall health is? 
1.   Excellent   2.   Very Good  3.   Good 
4.   Fair  5.   Poor  
2. At the present time, would you say your eyesight using both eyes (with 
glasses or contact lenses, it you wear them) 
1.   Excellent   2.   Very Good  3.   Good 
4.   Fair  5.   Poor  
3. How much of the time do you worry about your eyesight? 
1.   None of the time    2.  A little of the time  3. Some of the time  
4.   Most of the time    5.  All of the time 
4. How much pain or discomfort have you had in and around your eyes? 
would you say it is? 
1.   None  2.   Mild  3.   Moderate 
4.   Severe  5.   Very Severe  
PART - II 
Difficulty with Activities 
5. How much difficulty do you have reading ordinary 1 2 3 4 5 6 
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print in newspapers? 
6. How much difficulty do you have doing work or 
hobbies that require you to see well up close, such 
as looking, sewing, fixing things around the house of 
using hand tools? 
1 2 3 4 5 6 
7. Because of your eyesight, how much difficulty do your 
have finding something on a crowded shelf? 
1 2 3 4 5 6 
8. How much difficulty do you have reading street 
signs or the names of stores? 
1 2 3 4 5 6 
9. Because of your eyesight, how much difficulty do you 
have going down steps, stairs, or curbs in dim 
light or at night? 
1 2 3 4 5 6 
10. How much difficulty do you have noticing objects 
off to the side while you are walking along? 
1 2 3 4 5 6 
11. How much difficulty do you have seeing how 
people react to things your say? 
1 2 3 4 5 6 
12. How much difficulty do you have picking out and 
matching you own clothes? 
1 2 3 4 5 6 
13. How much difficulty do you have visiting with 
people in their homes, at parties, or in 
restaurants? 
1 2 3 4 5 6 
14. How much difficulty, do you have going out to see 
movies, plays or sports events? 
1 2 3 4 5 6 
 
Note : 
1. No difficulty at all 
2. A little difficulty 
3. Moderate difficulty  
4. Extreme difficulty 
5. Stopped doing this because of your eyesight 
6. Stopped doing this for other reasons or not  interested in doing this 
 
15. Now I’d like to ask about driving a car.  Are you currently driving, at 
least once in a while? 
1)  Yes (Skip to Q15c)   2)   No   
 
15a. If No, Ask : Have you never driven a care or have you given up driving? 
 1)  Never drove (Skip to Q 17)  2) Gave up 
 
15b. If gave up driving : was that mainly because of your eyesight, mainly for 
some other reason, or because of both your eyesight and other reasons?   
 1) Mainly eyesight    2) Mainly other reasons  
 3) Both eyesight and other reasons   
 81
 
15c.  If currently driving  : how much difficulty do you have driving the daytime in 
familiar places? 
  1) No difficultly at all    2) A little difficultly  
 3) Moderate difficulty    4) Extreme difficulty   
 
16. How much difficulty do you have driving at night? 
1) No difficulty at all   2) A little difficulty  
3) Moderate difficulty    4) Extreme difficulty  
5) Have you stopped doing this because of your eyesight  
6) Have you stopped doing this for other reasons or are you not 
interested in doing this ......... 
 
16a. How much difficulty do you have driving in difficult conditions, such as 
in bad weather, during rush hour, on the freeway, or in city traffic? 
 1) No difficult at all   2) A little difficulty  
 2) Moderate difficulty   4) Extreme difficulty  
 5) Have you stopped doing this because of your eyesight? 
 6) Have you stopped doing this for other reasons or are you not 
interested  
in doing this ......... 
  
17. Do you accomplish less than you would like because of your vision? 
1)  All of the time  2)  Most of the time  3) Some of the time   
4)   A little of the time  5)  None of the time    
 
18. Are you limited in how long you  can work or do other activities because of 
your vision?  
1) All of the time  2) Most of the time  3) Some of the time 
4) A little of the time 5) None of the time  
 
19. How much does pain or discomfort in or around your eyes, for example, 
burning , itching, or aching, keep you from doing what you’d like to be 
doing? 
1) All of the time  2) Most of the time  3) Some of the 
time  
4) A little of the time  5) None of the time  
 
20. I stay home most of the time because of my 
eyesight 
1 2 3 4 5 
21. I feel frustrated a lot of the time because of my 
eyesight 
1 2 3 4 5 
22. I have much less control over what I do, because 
of my eyesight 
1 2 3 4 5 
23. Because of my eyesight, I have to rely too 
much on what other people tell me  
1 2 3 4 5 
24. I need a lot of help from others because of my 
eyesight 
1 2 3 4 5 
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25. I worry about doing things that will 
embarrass myself or others, because of my 
eyesight. 
1 2 3 4 5 
 
Note: 
1. Definitely true 
2. Mostly true 
3. Not true 
4. Mostly false 
5. Definitely false 
 
 
 
 
 
SF 12 HEALTH SURVEY 
 
 
1. In general, would you say your health is, 
Excellent   (0)  Very good   (0)  Good   (0)  
Fair     (0)  Poor    (-2) 
 
2. Does your health now, limit you in activities like moving a table, pushing a 
vaccum cleaner or playing? 
Yes limited a lot   (4)    Yes limited a little  (2)  
No, non limited at all   (0) 
3. Does you health now limit you in climbing several flights of stairs? 
Yes limited a lot   (4)    Yes limited a little  (2)  
No, non limited at all   (0) 
During past 4 weeks have you had any problem as a result of your physical 
health? 
4. Accomplished less than you would like?  Yes  (1) No  (0) 
5. Were limited in the kind of work or other activities? Yes  (2) No  (0) 
 
During past 4 weeks have you had any problems as a result of emotional problems 
(feeling depressed or anxious) 
 
6. Accomplished less than you would like?   Yes  (7) No  (0) 
 
7. Didn’t do work or other activities as carefully as usual?   Yes  (6) No  (0) 
 
8. During the past 4 weeks, how much did pain interfere with your normal work 
(both working outside or housework)? 
Not at all  (0)  A little bit  (1)   Moderately  (1) 
Quite a bit  (2)  Extremely  (1) 
9. How much of the time during the past 4 weeks 1  (0) 2      3     4   5    (- 6      
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have you felt calm and peaceful? (-2) (-4) (-6) 10) (-10) 
10. 
How much of the time during the past 4 weeks 
did you have a lot of energy? 
1  (0) 
2      
(-1) 
3     
(-2) 
4   
(-3) 
5    (-
5) 
6      
(-6) 
11. 
How much of the time during the past 4 weeks 
have you felt downhearted and blue? 
1      
(-16) 
2      
(-11) 
3     
(-8) 
4   
(-5) 
5    (-
2) 
6      
(-0) 
12. 
During the past 4 weeks, how much of the time 
has your physical health or emotional problem 
interfered with your social activities (like 
visiting friends, relatives etc.,) 
1      
(-6) 
2      
(-8) * 
4   
(-6) 
5    (-
3) 
6      
(0) 
Note 
1.  All of the time   2. Most of the time   3. A good bit of the time 
4.  Some of the time  5. A little of the time  6.  None of the time  
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CLINICALLY USEFUL IMMUNOSUPPRESSIVE AGENTS32 
 
 
 
Generic Name 
(Class) 
Mechanism of Action Dosage Toxicity Precautions 
1. Cyclophosphamide 
(Alkylating agent) 
Miscoding and blocking 
of DNA replication  
1-2 mg / kg / d 1. Sterile hemorrhagic 
cystitis 
2. Alopecia 
3. Anemia 
4. Thrombocytopenia 
 Blood counts (2 weekly) 
 Urine analysis (2 
weekly) 
 Morning dosage 
 2-3 liters of fluid /day 
 Frequent voiding 
2. Chlorambucil 
(Alkylating agent) 
Miscoding and blocking 
of DNA replication 
0.1 mg/ kg/d 
Max dose : 18 mg / d 
1. Reversible bone 
marrow Suppression  
2. Leucopenia 
3. Azoospermia 
4. Leukemia’s 
 Blood counts (1-2 
weekly)  
 
3. Methotrexate (Folic 
acid antagonist) 
Inhibits the production of 
tetrahydrofolate (THF) 
thereby reducing 
synthesis of DNA. 
Enzyme inhibited is 
dihydrofolate reductase 
Single low dose 
pulsed therapy  
PO:7.5 - 12.5 mg/wk 
Max : 25 mg/wk 
1. Nausea 
2. Malaise / alopecia 
3. Ulcerative stomatitis  
4. Pancytopenia 
5. Hepatotoxicity  
 Blood counts (2wkly) 
 LFT mainly SGOT & 
SGPT (4 wkly) 
 Liver biopsy after 1.5 
gm  cumulative dose 
 Folinic acid 1 mg/d 
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4. Azathioprine (purine 
antagonist ) 
Interferes with synthesis 
of purine bases and 
therefore RNA and DNA 
synthesis 
PO : 1-2.5 mg / kg / 
d in one or more 
doses 
1. Myelosuppresion  
2. GI distress 
3. Secondary infections 
 Blood count (1-2 wkly) 
5. Cyclosporine A 
(Macrolide) 
Inhibits transcription of 
IL-2 and IL-4 in T cells 
thus suppressing 
activation and 
proliferation of T cells 
PO : 5-7 mg / kg/d 1. Nephrotoxic 
2. Gingival hyperplasia 
3. Nausea & Vomiting 
4. Hypertrichosis  
5. Systemic hypertension  
6. Mild anemia 
 Renal functions (4wkly) 
 Blood count (4 wkly)  
 Monitor serum level 
(150-200 ng/ml) 
6. FK – 506 
(Macrolide) 
Prevents transcription of   
IL-2 and IL-4 genes 
leading to inhibition of T-
helper cell proliferation 
and activation 
PO: 0.1 to 0.15 mg/ 
kg/d in two divided 
doses. 
1. Renal impairment  
2. Tremors  
3. Hyperglycemia 
 Serum creatinine 
(2wkly) 
 Blood count (2 wkly) 
 Maintain blood level 
below 20ng/ml 
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